LT4070800T - Kladribino gydymo schema, skirta išsėtinei sklerozei gydyti - Google Patents

Kladribino gydymo schema, skirta išsėtinei sklerozei gydyti

Info

Publication number
LT4070800T
LT4070800T LTEP22166610.0T LT22166610T LT4070800T LT 4070800 T LT4070800 T LT 4070800T LT 22166610 T LT22166610 T LT 22166610T LT 4070800 T LT4070800 T LT 4070800T
Authority
LT
Lithuania
Prior art keywords
multiple sclerosis
treating multiple
cladribine
regimen
cladribine regimen
Prior art date
Application number
LTEP22166610.0T
Other languages
English (en)
Lithuanian (lt)
Inventor
Giampiero De Luca
Arnaud Ythier
Alain Munafo
Maria Lopez-Bresnahan
Original Assignee
Merck Serono S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36227798&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT4070800(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Serono S.A. filed Critical Merck Serono S.A.
Publication of LT4070800T publication Critical patent/LT4070800T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/215IFN-beta
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
LTEP22166610.0T 2004-12-22 2005-12-20 Kladribino gydymo schema, skirta išsėtinei sklerozei gydyti LT4070800T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63866904P 2004-12-22 2004-12-22
EP04106909 2004-12-22

Publications (1)

Publication Number Publication Date
LT4070800T true LT4070800T (lt) 2025-01-10

Family

ID=36227798

Family Applications (3)

Application Number Title Priority Date Filing Date
LTEP22166610.0T LT4070800T (lt) 2004-12-22 2005-12-20 Kladribino gydymo schema, skirta išsėtinei sklerozei gydyti
LTEP18151634.5T LT3332789T (lt) 2004-12-22 2005-12-20 Kladribino režimas, skirtas išsėtinės sklerozės gydymui
LTPA2018503C LTC2805723I2 (lt) 2004-12-22 2018-02-20 Kladribino režimas, skirtas išsėtinei sklerozei gydyti

Family Applications After (2)

Application Number Title Priority Date Filing Date
LTEP18151634.5T LT3332789T (lt) 2004-12-22 2005-12-20 Kladribino režimas, skirtas išsėtinės sklerozės gydymui
LTPA2018503C LTC2805723I2 (lt) 2004-12-22 2018-02-20 Kladribino režimas, skirtas išsėtinei sklerozei gydyti

Country Status (25)

Country Link
US (2) US7713947B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (7) EP3332789B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (7) JP5795456B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR20070091662A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR052830A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (2) AU2005318190B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BRPI0517132B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (2) CA2588966C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (3) CY1112614T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (3) DK3332789T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (1) EA015799B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (2) ES3007339T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI4070800T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR18C1008I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (1) HRP20120228T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (3) HUE059133T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (2) IL183930A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LT (3) LT4070800T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LUC00064I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX2007007610A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO20073813L (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (4) PL1827461T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG160391A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (3) SI2805723T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2006067141A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3007339T3 (en) 2004-12-22 2025-03-19 Merck Serono Sa Cladribine regimen for treating multiple sclerosis
KR20090019810A (ko) * 2006-05-24 2009-02-25 라보라뚜와르 세로노 에스. 에이. 다발성 경화증 치료를 위한 클라드리빈 요법
EP2343074A1 (en) 2009-12-23 2011-07-13 Merck Serono S.A. Use of purine analogues for treating airway diseases
WO2011117267A1 (en) 2010-03-24 2011-09-29 Merck Serono Sa Cladribine treatment of multiple sclerosis in patient groups defined by genotype
EP2428201A1 (en) 2010-09-08 2012-03-14 Merck Serono S.A. Oral administration of nucleoside monophosphates
WO2012097867A1 (en) 2011-01-18 2012-07-26 Synthon Bv Cladribine particles and pharmaceutical compositions comprising them
GB201401465D0 (en) 2014-01-29 2014-03-12 Roach Arthur H Use of cladribine for treating autoimmune inflammatory disease
GB2564717A (en) * 2017-07-21 2019-01-23 Chord Therapeutics S A R L Use of cladribine for treating autoimmune neuromuscular disease
KR102743999B1 (ko) * 2017-11-24 2024-12-17 메르크 파텐트 게엠베하 진행 형태의 다발성 경화증의 치료에서 사용을 위한 클라드리빈 용법
GB2601786A (en) 2020-12-10 2022-06-15 Chord Therapeutics S A R L Use of cladribine for treating immune brain disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1269659A (en) 1984-08-06 1990-05-29 Brigham Young University Method for the production of 2'-deoxyadenosine compounds
US5310732A (en) 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US4964848A (en) * 1988-06-27 1990-10-23 Bloom Philip M Treatment of multiple sclerosis with lymphocytapheresis and chemo-immunosuppression
US5208327A (en) 1991-12-18 1993-05-04 Ortho Pharmaceutical Corporation Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine
US5641757A (en) 1994-12-21 1997-06-24 Ortho Pharmaceutical Corporation Stable 2-chloro-2'-deoxyadenosine formulations
DE69528080T2 (de) 1994-12-22 2003-06-05 Ortho Pharma Corp Lösliche arzneizusammensetzungen enthaltend 2-chloro-2'-deoxyadenosine
US6194395B1 (en) 1999-02-25 2001-02-27 Orthro-Mcneil Pharmaceutical, Inc. Cyclodextrin cladribine formulations
WO2000064918A1 (en) 1999-04-28 2000-11-02 Sterrenbeld Biotechnologie North America, Inc. METHOD FOR THE PRODUCTION OF 2-CHLORO-2'-DEOXYADENOSINE (CLADRIBINE) AND ITS 3,5-DI-O-p-TOLUOYL DERIVATIVE
DE10237146A1 (de) * 2002-08-13 2004-03-04 Medac Gesellschaft für klinische Spezialpräparate mbH Verwendung von Treosulfan und Derivaten davon zur Behandlung der Multiplen Sklerose
WO2004028462A2 (en) 2002-09-25 2004-04-08 Brigham Young University, Technology Transfer Office Method for the preparation of 2-halo-2'-deoxyadenosine compounds from 2'-deoxyguanosine
GB2394658A (en) * 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
MXPA05008998A (es) * 2003-02-25 2005-10-18 Applied Research Systems Uso combinado de ribavirina e interferon beta en enfermedades desmielinizantes.
BRPI0408895A (pt) 2003-03-28 2006-04-11 Ivax Corp formulações de cladribina para administração oral e transmucosal aperfeiçoada
DE602004028448D1 (de) 2003-03-28 2010-09-16 Ares Trading Sa Orale zubereitungen enthaltend cladribin
ES3007339T3 (en) 2004-12-22 2025-03-19 Merck Serono Sa Cladribine regimen for treating multiple sclerosis
KR20090019810A (ko) * 2006-05-24 2009-02-25 라보라뚜와르 세로노 에스. 에이. 다발성 경화증 치료를 위한 클라드리빈 요법

Also Published As

Publication number Publication date
JP5908863B2 (ja) 2016-04-26
US20100203017A1 (en) 2010-08-12
EP2275110A3 (en) 2011-04-27
SI4070800T1 (sl) 2025-03-31
PL1827461T3 (pl) 2012-07-31
KR20070091662A (ko) 2007-09-11
US7713947B2 (en) 2010-05-11
PL4070800T3 (pl) 2025-03-10
IL183930A0 (en) 2007-10-31
EP2805723A1 (en) 2014-11-26
JP2008524313A (ja) 2008-07-10
EP2805723B1 (en) 2018-01-17
MX2007007610A (es) 2007-08-03
US20090081163A1 (en) 2009-03-26
SG160391A1 (en) 2010-04-29
JP6290962B2 (ja) 2018-03-07
AR052830A1 (es) 2007-04-04
EP4070800A1 (en) 2022-10-12
HUE070333T2 (hu) 2025-05-28
EP3332789B1 (en) 2022-04-06
EP4070800B1 (en) 2024-10-16
FR18C1008I2 (fr) 2019-03-01
WO2006067141A1 (en) 2006-06-29
LTC2805723I2 (lt) 2022-04-25
LTPA2018503I1 (lt) 2018-03-12
FI4070800T3 (fi) 2025-01-14
LUC00064I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2018-02-14
CY1112614T1 (el) 2016-02-10
EA015799B1 (ru) 2011-12-30
BRPI0517132B8 (pt) 2021-05-25
CA3087419A1 (en) 2006-06-29
SI3332789T1 (sl) 2022-08-31
BRPI0517132A (pt) 2008-09-30
US8377903B2 (en) 2013-02-19
JP6430554B2 (ja) 2018-11-28
EP3332789A1 (en) 2018-06-13
AU2005318190A1 (en) 2006-06-29
JP6092945B2 (ja) 2017-03-08
CA2588966C (en) 2020-07-21
NO20073813L (no) 2007-09-21
EP2263678B1 (en) 2014-06-11
LT3332789T (lt) 2022-07-25
EP4523753A3 (en) 2025-05-28
HUE059133T2 (hu) 2022-10-28
EP2275110B1 (en) 2013-07-10
IL212421A0 (en) 2011-06-30
SI2805723T1 (en) 2018-02-28
PL3332789T3 (pl) 2022-08-22
JP5795456B2 (ja) 2015-10-14
JP2015180685A (ja) 2015-10-15
AU2011200768A1 (en) 2011-03-17
CA2588966A1 (en) 2006-06-29
BRPI0517132B1 (pt) 2020-02-18
LUC00064I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2018-03-28
DK2805723T3 (da) 2018-01-29
JP2013216664A (ja) 2013-10-24
DK3332789T3 (da) 2022-07-11
DK4070800T3 (da) 2025-01-02
CY1119790T1 (el) 2018-06-27
EP2263678A2 (en) 2010-12-22
ES3007339T3 (en) 2025-03-19
EP2263678A3 (en) 2011-04-27
EP1827461A1 (en) 2007-09-05
JP2018165271A (ja) 2018-10-25
EP1827461B1 (en) 2012-02-29
EP4523753A2 (en) 2025-03-19
EP2275110A2 (en) 2011-01-19
JP2017101061A (ja) 2017-06-08
JP2016138128A (ja) 2016-08-04
IL212421A (en) 2014-01-30
ES2921858T3 (es) 2022-09-01
CY2018006I1 (el) 2018-06-27
CA3087419C (en) 2023-03-07
HUS1800009I1 (hu) 2018-05-02
HRP20120228T1 (hr) 2012-04-30
CY2018006I2 (el) 2018-06-27
AU2011200768B2 (en) 2012-09-13
AU2005318190B2 (en) 2010-11-25
EA200701221A1 (ru) 2008-02-28
JP2020193206A (ja) 2020-12-03
FR18C1008I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2018-03-30
PL2805723T3 (pl) 2018-04-30

Similar Documents

Publication Publication Date Title
HUS1800009I1 (hu) Kladribin adagolási elõírás szklerózis multiplex kezelésére
ZA200808852B (en) Cladribine regimen for treating multiple sclerosis
IL179139A0 (en) Method for treating multiple sclerosis
IL183900A0 (en) Polymerization processes
EP1741656A4 (en) ELEVATOR
EP1741658A4 (en) LIFT DEVICE
IL180446A0 (en) Object process graph application controller-viewer
EP1792865A4 (en) ELEVATOR
EP1827491A4 (en) TREATMENT OF MULTIPLE SCLEROSIS
EP1812665A4 (en) MACHINE FOR HEAVY-HEAD EXTRACTION FOR CUTTED SURFACES
EP1754680A4 (en) LIFT DEVICE
EP1795483A4 (en) LIFT DEVICE
EP1798183A4 (en) ELEVATOR EQUIPMENT
EP1783085A4 (en) LIFT APPARATUS
TWI367216B (en) Process for stopping continuous polymerization
EP1741657A4 (en) LIFT DEVICE
EP1790611A4 (en) ELEVATOR EQUIPMENT
EP1783088A4 (en) LIFT DEVICE
EP1754679A4 (en) ELEVATOR EQUIPMENT
EP1741660A4 (en) ELEVATOR
EP1733993A4 (en) TOROID-VARIATORS
EP1792867A4 (en) ELEVATOR
EP1754681A4 (en) LIFT DEVICE
HU0400305D0 (en) Set for spine-fixture
EP1724229A4 (en) LIFT DEVICE